Description:
Kalorama Information is excited to present an updated market report on in vitro diagnostics (IVD) products, reflecting the latest insights as of Q3 2022, published in November 2022. This essential report examines the critical factors driving growth and shaping the IVD market in the latter half of 2022.
Report Highlights:
- Market Drivers in Q3 and H2 2022:
- Understanding the key trends influencing market growth during this period.
- Exploring the impact of COVID-19 on the IVD market and its ongoing effects.
- Identifying the major trends affecting the market, including product innovations and new developments.
Key Segments and Trends:
- Emerging Technologies: Focus on next-generation sequencing (NGS), personalized medicine, and mass spectrometry as growing segments capturing industry attention.
- Core Market Interests: Immunochemistry, point-of-care (POC) testing, and molecular diagnostics are highlighted as crucial areas of interest, anticipated to shape the future of IVD.
Market Dynamics:
- Innovation and Development: The IVD market is continuously evolving with new products and technologies, changes in global health spending, regulatory shifts in major markets, and emerging disease trends.
- Demand and Technology Movement: The report covers how the demand for testing and the movement of current and new technologies have demonstrated gains across most areas of the IVD market.
Expert Insights:
- Kalorama Information provides a comprehensive overview of the IVD market, leveraging the extensive experience of its authors and a commitment to presenting the most accurate data available.
- This report is essential for understanding the rapidly changing landscape of the IVD market and staying ahead in this dynamic industry.
For further details and to purchase directly, please contact us.
Sample Report: A sample is available as a PDF upon request.
Table: Global In Vitro Diagnostic, Sales by Product Segment, 2022 (in millions $)
| Segment | 2022 ($ million) | %Mkt |
| Clinical Chemistry | $XX Million | XX% |
| Immunoassays- non isotopic | ||
| Infectious disease | $XX Million | XX% |
| Other immunos | $XX Million | XX% |
| Blood bank screening | $XX Million | XX% |
| Drugs of Abuse | $XX Million | XX% |
| Diabetes HbA1c, lab | $XX Million | XX% |
| Hematology – Core Lab | $XX Million | XX% |
| Microbiology (ID/AST) | $XX Million | XX% |
| Microbiology (molecular) | $XX Million | XX% |
| Microbiology – Mass Spectrometry | $XX Million | XX% |
| Coagulation (PT/INR) | $XX Million | XX% |
| Coagulation, molecular | $XX Million | XX% |
| D-dimer | $XX Million | XX% |
| Histology/cytology | $XX Million | XX% |
| HPV, molecular | $XX Million | XX% |
| Nucleic acid assays/genetic tests | $XX Million | XX% |
| Blood grouping/typing | $XX Million | XX% |
| Blood bank molecular – NAT Screens | $XX Million | XX% |
| Circulating tumor cells | $XX Million | XX% |
| POC, OTC diabetes | $XX Million | XX% |
| POC, OTC other | $XX Million | XX% |
| POC, professional/hospital | $XX Million | XX% |
| Mass Spectrometry | $XX Million | XX% |
| Other (transplant testing, other, etc.) | $XX Million | XX% |
| IVD Market Total | $XX Million | XX% |
Source: Kalorama Information
